Preparation and application of allogeneic CAR-γδT cells targeting GPRC5D

By targeting GPRC5D allogeneic CAR-γδT cells and using high-affinity antibodies to construct CAR-γδT cells, the problem of reduced efficacy and drug resistance in multiple myeloma treatment was solved, and efficient killing of GPRC5D-positive tumor cells was achieved. A new targeted therapy is provided.

CN118108846BActive Publication Date: 2024-11-26WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410158090.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-04
Publication Date
2024-11-26
Estimated Expiration
2044-02-04

AI Technical Summary

Technical Problem

The treatment of multiple myeloma still faces problems of reduced efficacy and drug resistance. Existing targeted treatments such as BCMA and CD38 have reduced efficacy and shedding, and new targeted treatment methods are needed.

Method used

Targeting GPRC5D allogeneic CAR-γδ T cells were prepared, and CAR-γδ T cells were constructed through anti-GPRC5D antibodies or their antigen-binding fragments, and using their high affinity and specificity to recognize and kill GPRC5D-positive tumor cells.

Benefits of technology

The efficient killing activity of multiple myeloma cells is achieved, providing a potential new targeted therapy solution, overcoming the limitations of existing target therapy and improving the safety and effectiveness of the treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118108846B_ABST
    Figure CN118108846B_ABST
Patent Text Reader

Abstract

The present invention discloses the preparation and application of allogeneic CAR-γδT cells targeting GPRC5D, and relates to the field of biomedicine. The anti-GPRC5D antibody or antigen-binding fragment thereof provided by the present invention includes CDRs shown in SEQ ID NOs: 1 to 3, 4 to 6 or CDRs shown in SEQ ID NOs: 10 to 12, 13 to 15. In addition, the antibodies obtained by screening are used as antigen-binding domains to construct chimeric antigen receptors, and γδT cells isolated from the peripheral blood of healthy donors are used to prepare CAR-γδT cells, which have obvious killing activity against GPRC5D-positive multiple myeloma cell lines. The present invention can be used to prepare drugs for the diagnosis, prevention and treatment of multiple myeloma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to the preparation and application of allogeneic CAR-γδT cells targeting GPRC5D. Background Art

[0002] Multiple myeloma (MM) is a blood tumor characterized by abnormal proliferation of plasma cells (PCs) and the production of a large amount of pathological immunoglobulins in the body. Among blood tumors, its incidence is second only to lymphoma, accounting for about 10% of blood system malignancies, with a male-female ratio of 1.6:1, and most patients are >40 years old. In the past two decades, with the introduction of immunomodulatory drugs (lenalidomide, pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, ixazomib) and histone deacetylase inhibitors, the treatment of MM has made significant progress. Since the late 1980s, these advances have almost doubled the 5-year survival rate of MM patients. Although the diagnosis and treatment of MM in my country has made significant progress and gradually caught up with the international level, MM is still a non-radical disease, and most patients will eventually relapse, and its treatment still faces great challenges. Therefore, in order to improve the problem of reduced efficacy during treatment, it is necessary to develop safer, more effective and more diverse new drugs.

[0003] GPRC5D (G protein-coupled receptor class C group 5member D) is a 7-transmembrane protein discovered at the beginning of this century. It is an orphan receptor of the G protein-coupled receptor (GPCR) C5 family. GPRC5D mRNA is highly expressed in multiple myeloma cell lines, while GPRC5D mRNA is not highly expressed in any normal tissue except hair follicles, which makes it a potential effective target in multiple myeloma immunotherapy. Its expression on multiple myeloma cells is not related to BCMA expression, and because it is a 7-transmembrane protein, it is not easy to fall off in the serum, but this phenomenon exists in other surface antigens (such as BCMA, CD38) and may lead to reduced efficacy or drug resistance.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] The purpose of the present invention is to provide the preparation and application of allogeneic CAR-γδT cells targeting GPRC5D.

[0006] The present invention is achieved in that:

[0007] In the first aspect, an embodiment of the present invention provides an anti-GPRC5D antibody or an antigen-binding fragment thereof, which includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region include: HCDR1, HCDR2 and HCDR3 whose amino acid sequences are sequentially shown in SEQ ID No.1 to 3, and LCDR1, LCDR2 and LCDR3 whose amino acid sequences are sequentially shown in SEQ ID No.4 to 6; or, HCDR1, HCDR2 and HCDR3 whose amino acid sequences are sequentially shown in SEQ ID No.10 to 12, and LCDR1, LCDR2 and LCDR3 whose amino acid sequences are sequentially shown in SEQ ID No.13 to 15.

[0008] In a second aspect, an embodiment of the present invention provides an isolated nucleic acid encoding the antibody or antigen-binding fragment thereof as described in the above embodiments.

[0009] In a third aspect, an embodiment of the present invention provides a recombinant vector comprising the isolated nucleic acid as described in the preceding embodiments.

[0010] In a fourth aspect, an embodiment of the present invention provides a host cell comprising the recombinant vector as described in the above embodiment.

[0011] In a fifth aspect, an embodiment of the present invention provides a method for preparing an anti-GPRC5D antibody or an antigen-binding fragment thereof, which comprises: culturing the host cell as described in the above embodiment to obtain the anti-GPRC5D antibody or an antigen-binding fragment thereof.

[0012] In a sixth aspect, an embodiment of the present invention provides a chimeric antigen receptor, wherein the antigen binding domain of the chimeric antigen receptor comprises the anti-GPRC5D antibody or antigen binding fragment thereof as described in the above embodiments.

[0013] In a seventh aspect, an embodiment of the present invention provides a CAR-γδT cell, comprising: a chimeric antigen receptor as described in the above embodiment.

[0014] In an eighth aspect, embodiments of the present invention provide the use of an anti-GPRC5D antibody or antigen-binding fragment thereof as described in the preceding embodiments, or an isolated nucleic acid as described in the preceding embodiments, or a recombinant vector as described in the preceding embodiments, or a host cell as described in the preceding embodiments, or a chimeric antigen receptor as described in the preceding embodiments, or a CAR-γδT cell as described in the preceding embodiments for detecting GPRC5D for non-disease diagnosis purposes and / or treatment purposes, or for preparing products for preventing or treating tumors, or for preparing products for detecting GPRC5D.

[0015] In the ninth aspect, an embodiment of the present invention provides a cell injection solution, which includes: an anti-GPRC5D antibody or an antigen-binding fragment thereof as described in the preceding embodiment, or an isolated nucleic acid as described in the preceding embodiment, or a recombinant vector as described in the preceding embodiment, or a host cell as described in the preceding embodiment, or a chimeric antigen receptor as described in the preceding embodiment, or a CAR-γδT cell as described in the preceding embodiment.

[0016] The present invention has the following beneficial effects:

[0017] The present invention provides an anti-GPRC5D antibody and an antigen-binding fragment thereof, comprising a CDRs sequence as shown in SEQ ID NO: 1-6 or 9-14, which can be used for binding to GPRC5D with a KD of ≤10 -8 M~10 -9 M has a high affinity and specificity to bind to the GPRC5D antigen. In addition, the anti-GPRC5D antibody or antigen-binding fragment thereof provided by the present invention can be used as an antigen-binding domain to construct CAR-γδT cells, and the prepared CAR-γδT cells have excellent killing activity against GPRC5D-positive tumors such as multiple myeloma. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0019] Figure 1 To identify positive reaction clones using ELISA;

[0020] Figure 2 The purified scFv-hFc fusion protein was identified by SDS-PAGE;

[0021] Figure 3 ELISA was used to identify the reactivity of recombinant scFv-hFc antibodies with antigens;

[0022] Figure 4 Identification of the specific binding of GPRC5D antibody to MM natural target cells;

[0023] Figure 5 To verify the killing effect of GPRC5D CAR-γδT cells on target cells in vitro for RTCA;

[0024] Figure 6 To verify the anti-tumor activity of CAR-γδT cells in the MM.1S xenograft model; DETAILED DESCRIPTION

[0025] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0026] In one aspect, an embodiment of the present invention provides an anti-GPRC5D antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise:

[0027] The amino acid sequences of HCDR1, HCDR2 and HCDR3 are shown in SEQ ID No.1 to 3, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID No.4 to 6; or,

[0028] The amino acid sequences of HCDR1, HCDR2 and HCDR3 are shown in SEQ ID Nos. 10 to 12, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID Nos. 13 to 15, respectively.

[0029] The antibody or antigen-binding fragment thereof provided by the present invention can be -8 M, KD≤10 -9 The affinity of M.

[0030] In an optional embodiment, the antibody or antigen-binding fragment thereof provided by the present invention can be used with a KD of ≤6.23×10 -8 M or KD≤3.58×10 -9 The affinity of M.

[0031] In some embodiments, the heavy chain variable region and the light chain variable region further comprise a framework region.

[0032] The "framework region" or "FR" region herein refers to the region other than the CDR in the heavy chain variable region and the light chain variable region of an antibody. Specifically, the heavy chain framework region can be further subdivided into adjacent regions separated by CDRs, including HFR1, HFR2, HFR3 and HFR4 regions; the light chain framework region can be further subdivided into adjacent regions separated by LCDRs, including LFR1, LFR2, LFR3 and LFR4 regions. The heavy chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs (arranged from the amino terminus to the carboxyl terminus): HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by arranging and connecting the following numbered CDRs and FRs (arranged from the amino terminus to the carboxyl terminus): LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.

[0033] In some embodiments, the amino acid sequences of the heavy chain variable region and the light chain variable region are shown in SEQ ID NOs: 7 to 8, respectively.

[0034] In some embodiments, the amino acid sequences of the heavy chain variable region and the light chain variable region are shown in SEQ ID NOs: 16-17, respectively.

[0035] In some embodiments, the antibody or antigen-binding fragment thereof further comprises a constant region. The constant region comprises a heavy chain constant region and / or a light chain constant region. The light chain of a full-length antibody comprises a light chain variable region VL and a constant region CL, VL is at the amino terminus of the light chain, the CL domain is at the carboxyl terminus, and the light chain comprises a κ chain or a λ chain; the heavy chain of a full-length antibody comprises a heavy variable region VH and a constant region CH, VH is at the amino terminus of the heavy chain, and the CH domain is at the carboxyl terminus.

[0036] In some embodiments, the constant region is selected from the constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE and IgD.

[0037] In some embodiments, the species of origin of the constant region is rabbit, donkey, deer, cow, horse, pig, sheep, rat, mouse, dog, cat, mink, chicken, duck, goose or human.

[0038] In some embodiments, the antibody is selected from any one of a monoclonal antibody, a polyclonal antibody, a multispecific antibody, a murine antibody, a chimeric antibody, and a full-length antibody.

[0039] In some embodiments, the antigen-binding fragment is selected from the F(ab') 2 , Fab', Fab, Fv and scFv (single-chain antibody).

[0040] In some embodiments, when the antigen-binding fragment is scFv, the amino acid sequence of the scFv is as shown in SEQ ID NO:9 or 18.

[0041] It is understood that an "antigen binding fragment" is a portion of a complete antibody, and the antigen binding fragment can specifically bind to the antigen to which the complete antibody binds. It is easy for a person skilled in the art to understand based on the contents described in the present invention that an antigen binding fragment can be prepared by methods known in the art, for example, by enzymatic digestion (including pepsin or papain) and / or by chemical reduction to split disulfide bonds, and can also be synthesized by recombinant genetics technology or by an automatic peptide synthesizer (such as the automatic peptide synthesizer of Applied BioSystems).

[0042] A single chain antibody (scFv) is an antibody formed by connecting the heavy chain variable region and the light chain variable region of an antibody through a short peptide (linker) of 15 to 20 amino acids. On the other hand, an embodiment of the present invention also provides an isolated nucleic acid encoding an antibody or an antigen-binding fragment thereof as described in any of the above embodiments.

[0043] On the other hand, an embodiment of the present invention further provides a recombinant vector comprising the isolated nucleic acid as described in any of the above embodiments.

[0044] In some embodiments, the recombinant vector is an expression vector or a cloning vector. The recombinant vector may refer to any recombinant polynucleotide construct, which can directly or indirectly (such as packaged into a virus) introduce the target DNA fragment into the host cell by transformation, transfection or transduction to express the target gene. One type of vector is a plasmid, i.e., a circular double-stranded DNA molecule, which can connect the target DNA fragment to the plasmid ring; another type can be a viral vector, which can connect the target DNA fragment to the viral genome (such as adenovirus, adeno-associated virus, retrovirus, slow virus, oncolytic virus). After these vectors enter the host cell, the target gene can be expressed.

[0045] On the other hand, an embodiment of the present invention further provides a host cell, which contains the recombinant vector as described in any of the above embodiments.

[0046] In some embodiments, the host cell includes at least one of a prokaryotic host cell, a eukaryotic host cell, and a bacteriophage. The prokaryotic host cell may be Escherichia coli, Streptomyces, or Bacillus subtilis, etc. The eukaryotic host cell may be 293 cells, 293T cells, 293FT cells, CHO cells, COS cells, Per6, Saccharomyces cerevisiae, Pichia pastoris, Hansen yeast, Candida, some insect cells, and plant cells. 293 series cells, Per6 cells, and CHO cells are commonly used mammalian cells for producing antibodies or recombinant proteins, and are well known to those of ordinary skill in the art.

[0047] On the other hand, an embodiment of the present invention further provides a method for preparing an anti-GPRC5D antibody or an antigen-binding fragment thereof, comprising: culturing the host cell as described in any of the above embodiments to obtain the anti-GPRC5D antibody or an antigen-binding fragment thereof.

[0048] The present invention does not particularly limit the culture conditions of the host cells, and the culture conditions that enable the host cells to express and produce the anti-GPRC5D antibody can be obtained based on conventional technical knowledge.

[0049] On the other hand, an embodiment of the present invention further provides a chimeric antigen receptor, wherein the antigen binding domain of the chimeric antigen receptor comprises the anti-GPRC5D antibody or antigen binding fragment thereof described in any of the aforementioned embodiments.

[0050] In some embodiments, the chimeric antigen receptor further comprises a signal peptide, a hinge region, a transmembrane region and a signal transduction domain.

[0051] In some embodiments, the signaling domain comprises CD3ζ.

[0052] In some embodiments, the signal transduction domain also includes a 4-1BB intracellular region.

[0053] On the other hand, an embodiment of the present invention further provides a CAR-T cell, comprising: a chimeric antigen receptor as described in any of the above embodiments;

[0054] In some embodiments, the CAR-T cells are selected from any one of CAR-αβT cells and CAR-γδT cells.

[0055] γδT cells are a subset of T cells in the immune system that express a T cell receptor (TCR) composed of γ and δ chains, unlike αβT cells, which express a TCR composed of α and β chains. γδT cells are distributed in multiple tissues of the body, including the skin, intestines, and lungs, and are involved in various immune responses, such as fighting infection and regulating inflammation. They are also thought to play a role in recognizing and destroying cancer cells. Compared with αβT cells, γδT cells have a more limited TCR diversity and their functions are more similar to innate immunity. They can recognize antigens in a manner that does not require the mediation of major histocompatibility complex (MHC) molecules, which is the main way αβT cells recognize antigens. In contrast, γδT cells can recognize a variety of antigens, including lipids and stress-induced molecules.

[0056] CAR-γδT is a genetically modified γδT cell with the ability to target cancer cells. CAR stands for chimeric antigen receptor, which can be constructed by combining the antigen binding domain of an antibody with the signal transduction domain of a T cell receptor (TCR). CAR-γδT cells can recognize and bind to antigens on the surface of cancer cells through the antigen binding domain of CAR, thereby killing these cancer cells. Compared with αβT cells, γδT cells have a wider range of ligand specificity and higher killing activity, so they are considered to be a better cell therapy carrier. At the same time, given that they can recognize antigens in a way that does not require the mediation of major histocompatibility complex (MHC) molecules, more research is also devoted to developing them as an allogeneic cell therapy product. In addition, γδT cells have relatively low sensitivity to immunosuppressive factors in the tumor microenvironment, so they have great potential in treating tumors.

[0057] Autologous CAR-T cell therapy has the advantages of no immune rejection and can persist in the body for a long time. However, there are some limitations of autologous CAR-T cell therapy, such as high preparation cost, low number of T cells in AML patients with multiple lines of treatment or impaired T cell function after chemotherapy, resulting in decreased quality, T cell dysfunction in patients, and long manufacturing cycle, which makes patients miss the best time for treatment. CAR-γδT cells are a type of allogeneic CAR-T cells. Allogeneic CAR-T cells are derived from allogeneic sources or T cells derived from iPSCs, and are also called universal CAR-T cells. The development of this universal cell therapy can overcome most of the shortcomings of autologous CAR-T cell therapy, such as large-scale and industrialized manufacturing of standardized processes, and reduce costs, and can prepare a large number of CAR-T / γδT cells from a single donor. Allogeneic CAR-γδT cells can be frozen, allowing patients to receive treatment immediately and not miss the best time for treatment. It simplifies the process of introducing multiple modifications in a single cell product, as well as the standardization of donor-based selection and processing of CAR-γδT cell products. Autologous CAR-T cells are usually used to prepare a CAR-T product only once for that patient, while allogeneic cells can be administered repeatedly using these ready-made products if needed.

[0058] At present, CAR-γδT cells have shown good anti-tumor effects in in vitro and in vivo experiments and have been preliminarily verified in clinical trials. The antibody or antigen-binding fragment thereof provided in the embodiment of the present invention can be used as the antigen-binding domain of CAR to construct CAR-γδT cells. It has been verified that the constructed GPRC5D-targeted CAR-γδT cells have high killing activity against GPRC5D-positive tumors or GPRC5D-positive tumor cell lines.

[0059] On the other hand, an embodiment of the present invention also provides an anti-GPRC5D antibody or antigen-binding fragment thereof as described in any of the preceding embodiments, or an isolated nucleic acid as described in any of the preceding embodiments, or a recombinant vector as described in any of the preceding embodiments, or a host cell as described in any of the preceding embodiments, or a chimeric antigen receptor as described in any of the preceding embodiments, or a CAR-T cell as described in any of the preceding embodiments for use in detecting GPRC5D for non-disease diagnosis purposes and / or treatment purposes, or in preparing products for preventing or treating tumors, or in preparing products for detecting GPRC5D.

[0060] There are many situations in which GPRC5D is detected for non-disease diagnosis and / or treatment purposes, for example, when the sample to be tested is an environmental sample or an artificially prepared sample, the purpose of the detection is non-disease diagnosis and / or treatment purposes. In some embodiments, the product includes: at least one of an immune cell, a reagent, a kit, a drug, and a pharmaceutical composition.

[0061] In some embodiments, the tumor comprises a GPRC5D-positive tumor.

[0062] In some embodiments, the tumor comprises multiple myeloma.

[0063] As used herein, "treating" includes preventing or alleviating a condition, reducing the rate at which a condition develops or develops, reducing the risk of developing a condition, preventing or delaying the development of symptoms associated with a condition, reducing or stopping symptoms associated with a condition, producing complete or partial reversal of a condition, curing a condition, or a combination of the above.

[0064] For cancer, "treatment" can refer to inhibiting or slowing the growth, reproduction, or metastasis of tumors or malignant cells, or some combination of the above. For tumors, "treatment" includes eliminating all or part of the tumor, inhibiting or slowing tumor growth and metastasis, preventing or delaying the development of the tumor, or some combination of the above.

[0065] On the other hand, an embodiment of the present invention further provides a cell injection solution, which includes: an anti-GPRC5D antibody or an antigen-binding fragment thereof as described in any of the preceding embodiments, or an isolated nucleic acid as described in any of the preceding embodiments, or a recombinant vector as described in any of the preceding embodiments, or a host cell as described in any of the preceding embodiments, or a chimeric antigen receptor as described in any of the preceding embodiments, or a CAR-T cell as described in any of the preceding embodiments.

[0066] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0067] Example 1 Preparation of GPRC5D recombinant protein

[0068] The purchased human pMD18-GPRC5D plasmid was used as a template for PCR amplification. The full-length sequence of GPRC5D was obtained by agarose gel electrophoresis. The GPRC5D sequence was then cloned into the pcDNA3.1 expression vector with a His tag at the C-terminus using the pcDNA3.1 vector as a backbone. Then, 293FT was transiently transfected and FreeStyle TM The cells were cultured in a serum-free medium (Life Technologies) in a shaking flask for 72 h, and the cell pellets were collected and the recombinant GPRC5D full-length protein was purified via the His tag.

[0069] Example 2 Cell fusion and hybridoma screening

[0070] (1) Animal immunization

[0071] 5-6 week old Balb / c female mice were used as immunized animals, and the immunization dose was 100 μg / mouse. For the first immunization, 100 μl of Freund's complete adjuvant (Sigma) was mixed with an equal volume of recombinant GPRC5D protein, and multiple subcutaneous injections were performed after sufficient emulsification. After an interval of 2 weeks, an equal volume of Freund's incomplete adjuvant (Sigma) was mixed with the recombinant protein, and multiple subcutaneous injections were performed after sufficient emulsification. The booster immunization was performed 4 times in total. On the 10th day after the last booster immunization, blood was collected to detect the antibody titer of the mice. Three days before cell fusion, 100 μg of recombinant protein was intraperitoneally impacted once.

[0072] (2) Cell fusion and hybridoma screening

[0073] Under sterile conditions, mouse spleen was taken to prepare a suspension rich in B cells, and cell fusion was performed with SP2 / 0 according to the classic PEG (Sigma) method. The fused cells were resuspended in HAT medium for culture. Fresh HAT medium was used for half-medium replacement culture on the 5th and 10th days after fusion. ELISA was performed to screen positive clones on the 11th-15th day after fusion.

[0074] ELISA screening was performed using a 96-well plate. Briefly, GPRC5D recombinant protein was coated at 100 ng / well at 4°C overnight on the bottom of the well plate, 50 μl of hybridoma supernatant was collected and added to the coated 96-well plate, incubated and washed twice, and developed using HRP-conjugated anti-mouse IgG antibody and chemiluminescent reagent (Biyuntian Biotechnology Co., Ltd.), and read on an ELISA reader at a wavelength of 450 nm. Based on the above ELISA analysis results, two optimal hybridoma clones (named 1# and 31#, respectively) were finally determined ( Figure 1 ) for subsequent experiments such as sequence cloning and affinity analysis.

[0075] (3) Sequencing analysis of specific antibodies

[0076] Hybridoma antibody variable region sequence cloning: The best hybridoma clone cells in the logarithmic growth phase were collected, RNA was extracted with Trizol (Invitrogen) and reverse transcribed (PrimeScriptTM Reverse Transcriptase, Takara). The cDNA obtained by reverse transcription was amplified by PCR using mouse Ig-Primer Set (Novagen) and then sequenced to finally obtain the heavy chain and light chain variable region sequences. The variable region CDR sequences of the heavy chain and light chain and the single-chain antibody sequence (scFv) are shown in Table 1.

[0077] Table 1 CDR sequences and single-chain antibody sequences (scFv) contained in the heavy and light chain variable regions of mouse monoclonal antibodies

[0078]

[0079]

[0080] Example 3 Expression, purification and reactivity of single-chain antibody (scFv) with antigen

[0081] A single-chain antibody (scFv) expression platform was constructed based on a eukaryotic expression vector, and hybridoma clones 1 # and 31 # The VH and VL gene fragments were constructed in series on the pcDNA3.1 vector using (G4S)3linker. The constructed expression vector was expressed and purified using the HEK293T eukaryotic protein expression system. SDS-PAGE identification showed that the size of the single-chain antibody (scFv) was consistent with the theoretical molecular weight ( Figure 2 ), the sequence of the single-chain antibody is shown in Table 1.

[0082] To identify the reactivity of single-chain antibody (scFv) with antigen, 200 ng / well of GPRC5D recombinant protein was coated on the ELISA plate in advance, the plate was blocked after overnight at 4°C, and different amounts of recombinant antibody (dilution: 10 2 ~10 -5 μg / mL), added secondary antibody for washing, color development, terminated reaction, and measured the optical density (OD450) at 450nm using a microplate reader, and determined the binding capacity using a four-parameter nonlinear regression curve fitting. The results showed that both single-chain antibodies (scFv) of GPRC5D had high specificity binding to GPRC5D recombinant protein ( Figure 3 ).

[0083] Example 4 Analysis of antibody binding to endogenously expressed GPRC5D

[0084] Human multiple myeloma cell lines MM.1S and RPMI-8226 with positive GPRC5D expression, as well as human lymphoma cell lines with negative GPRC5D expression, were selected for flow cytometry analysis. The results showed that MM.1S and RPMI-8226 cells with positive GPRC5D expression were able to stain almost 100% positive with the two GPRC5D single-chain antibodies (scFv), while human lymphoma cell lines and human acute myeloid leukemia cells with negative GPRC5D expression were negative. This indicates that both GPRC5D single-chain antibodies (scFv) can specifically recognize the GPRC5D molecules endogenously expressed in cells ( Figure 4 ).

[0085] Example 5 GPRC5D antibody affinity determination

[0086] The affinity of the single-chain antibody (scFv) was verified by surface plasmon resonance, and the highest binding was determined to be 31 #(3.58×10 -9 ), followed by 1 # (6.23×10 -8 ), and the dissociation rates of the two antibodies were also slow. In summary, the Biacore data showed that both single-chain antibodies (scFv) of GPRC5D could bind to the GPRC5D antigen, and the specific data of the detection are shown in Table 2.

[0087] Table 2 Summary of antibody affinity data

[0088] Antibody Ka(1 / Ms) kd(1 / s) KD(M) <![CDATA[1 # ]]> <![CDATA[4.12×10 5 ]]> <![CDATA[2.56×10 -2 ]]> <![CDATA[6.23×10 -8 ]]> <![CDATA[31 # ]]> <![CDATA[1.5×10 7 ]]> <![CDATA[5.37×10 -2 ]]> <![CDATA[3.58×10 -9 ]]>

[0089] Example 6 Allogeneic γδT cell expansion and CAR-γδT cell construction

[0090] 10 mL of peripheral blood from healthy adult donors was collected in a sterile anticoagulant tube. First, the blood was diluted 1:1 with an equal volume of PBS and mixed by inverting. 3 mL of lymphocyte separation solution was added to each separation tube, centrifuged at room temperature at 1500 rpm for 1 min, and the diluted blood was added to the separation tube after removal, and centrifuged at room temperature at 1500 rpm for 15 min (the speed increase gear was adjusted to 2, and the speed decrease gear was adjusted to 2). The centrifuged separation tube was divided into three layers, the top layer was plasma, the milky white circle in the middle layer was lymphocytes, and the bottom layer was red blood cells; insert the gun tip into the white layer, slowly draw lymphocytes into a new 15 ml centrifuge tube, add an appropriate amount of PBS to the tube, mix well, and centrifuge at 1500 rpm for 5 min. Discard the supernatant, add an appropriate amount of PBS to resuspend, mix well by inverting, and centrifuge at 1500 rpm for 5 min. Repeat the wash once. After discarding the supernatant, the cells were resuspended in an appropriate amount of RPMI1640 complete medium (serum inactivated) containing 1.00 μg / ml to 4 μg / ml of zoledronic acid, and the lymphocytes were counted using a cell counter. After counting, the cells were adjusted to an appropriate density and added to the cell culture system to stimulate the proliferation and activation of γδT cells.

[0091] Select single chain antibody sequence (scFv)1 # and 31 #GPRC5D-CAR was constructed with the following structure: CD8αsignalpeptide-GPRC5D scFv-CD8αhinge-CD28αTm-4-1BB-CD3ζ-P2A-EGFP. HEK293T cells were used as lentiviral packaging cells, and lentiviral packaging was performed using a three-plasmid packaging system (psPAX2, pMD2.G, CAR-γδT vector). After 48 hours, the supernatant virus solution was collected, concentrated by ultracentrifugation, coated with RetroNectin protein in advance, and concentrated virus was added to infect γδT cells. After 48 hours of infection, the transfection efficiency of GPRC5D CAR-γδT cells was evaluated by flow cytometry to be above 80.00%.

[0092] Example 7 Evaluation of the killing effect of allogeneic CAR-γδT cells on target cells in vitro

[0093] GPRC5D+-Hela cells were added to a 96-well plate for non-labeled killing detection instrument (RTCA) and a common 96-well cell culture plate at 5000 cells per well and 100 μL / well (duplicate wells), respectively. The RTCA-specific 96-well plate was placed in the instrument and cultured until the Cell Index value was between 1.0 and 2.0. The prepared GPRC5D CAR-γδT cells were then co-incubated at an effector-target ratio of 2:1. The RTCA monitoring time was 65 hours to evaluate its killing activity. The results are as follows Figure 5 As shown in Figure 3, both GPRC5D CAR-γδTs have strong killing activity against GPRC5D+-Hela cells. # The killing activity is better than 1 # ( Figure 5 Middle A), weak killing activity against wild-type Hela ( Figure 5 (middle B).

[0094] Example 8 Anti-tumor experiment in xenograft mouse model

[0095] The in vivo anti-tumor activity of CAR-γδT targeting GPRC5D (GPRC5D CAR-γδT cells in Example 6) was evaluated by xenograft mouse model. The NCG mouse multiple myeloma model was established using the MM.1S cell line for evaluation. 31#GPRC5D CAR-γδT with strong in vitro killing activity was selected for in vivo mouse experiments.

[0096] 5 × 10 NCG mice were injected via tail vein 6 A multiple myeloma (MM) mouse tumor model was established using MM.1S-mCherry.ffLuc cells to validate the GPRC5D CAR-γδT (31 #) in vivo. On the 5th day after inoculation, NCG mice were randomly divided into 3 groups, 5 mice in each group, and injected with 1×10 7 NTγδT cells, 1×10 7 GPRC5D CAR-γδT (31 # ) cells, and a control group injected with PBS was set up. The growth status and survival of the mice were observed every day, and the survival period was recorded. The results showed that GPRC5D CAR-γδT (31 # ) treatment group observed a significant delay in tumor progression, and the survival time of tumor-bearing mice was significantly prolonged ( Figure 6 ).

[0097] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. An anti-GPRC5D antibody or an antigen-binding fragment thereof, characterized in that: It includes a heavy chain variable region and a light chain variable region, and the heavy chain variable region and the light chain variable region include: The amino acid sequences of HCDR1, HCDR2 and HCDR3 are shown in SEQ ID Nos. 1 to 3, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID Nos. 4 to 6; Or the amino acid sequences of HCDR1, HCDR2 and HCDR3 are shown in SEQ ID Nos.10 to 12, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID Nos.13 to 15.

2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The heavy chain variable region and light chain variable region also include framework regions.

3. The antibody or antigen-binding fragment thereof according to claim 2, characterized in that: The amino acid sequences of the heavy chain variable region and the light chain variable region are shown in SEQ ID NOs: 7 to 8, respectively.

4. The antibody or antigen-binding fragment thereof according to claim 2, characterized in that: The amino acid sequences of the heavy chain variable region and the light chain variable region are shown in SEQ ID NOs: 16-17, respectively.

5. The antibody or antigen-binding fragment thereof according to claim 2, characterized in that: The antibody or antigen-binding fragment thereof also includes a constant region.

6. The antibody or antigen-binding fragment thereof according to claim 5, characterized in that: The constant region is selected from any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE and IgD.

7. The antibody or antigen-binding fragment thereof according to claim 5, characterized in that: The species origin of the constant region is cow, horse, pig, sheep, rat, mouse, dog, cat, rabbit, donkey, deer, mink, chicken, duck, goose or human.

8. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antibody is selected from any one of a monoclonal antibody, a polyclonal antibody, a multispecific antibody, a mouse antibody, a chimeric antibody and a full-length antibody.

9. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The antigen-binding fragment is selected from any one of F(ab')2, Fab', Fab, Fv and scFv of an antibody.

10. The antibody or antigen-binding fragment thereof according to claim 9, characterized in that: When the antigen-binding fragment is scFv, the amino acid sequence of the scFv is shown in SEQ ID NO: 9 or 18.

11. An isolated nucleic acid, characterized in that It encodes the antibody or antigen-binding fragment thereof according to any one of claims 1 to 10.

12. A recombinant vector, characterized in that: It contains the isolated nucleic acid as claimed in claim 11.

13. A host cell, characterized in that It contains the recombinant vector as claimed in claim 12.

14. A method for preparing an anti-GPRC5D antibody or an antigen-binding fragment thereof, characterized in that: It includes: Cultivate the host cell as claimed in claim 13 to obtain an anti-GPRC5D antibody or an antigen-binding fragment thereof.

15. A chimeric antigen receptor, characterized in that The antigen binding domain of the chimeric antigen receptor comprises the anti-GPRC5D antibody or antigen binding fragment thereof according to any one of claims 1 to 10.

16. The chimeric antigen receptor according to claim 15, characterized in that The chimeric antigen receptor further comprises a signal peptide, a hinge region, a transmembrane region and a signal transduction domain.

17. The chimeric antigen receptor according to claim 16, characterized in that The signal transduction domain includes CD3ζ.

18. The chimeric antigen receptor according to claim 17, characterized in that The signal transduction domain also includes the 4-1BB intracellular region.

19. A CAR-γδT cell, characterized in that: It includes: The chimeric antigen receptor according to any one of claims 15 to 18.

20. Use of an anti-GPRC5D antibody or antigen-binding fragment thereof as claimed in any one of claims 1 to 10, or an isolated nucleic acid as claimed in claim 11, or a recombinant vector as claimed in claim 12, or a host cell as claimed in claim 13, or a chimeric antigen receptor as claimed in any one of claims 15 to 18, or a CAR-γδT cell as claimed in claim 19 in detecting GPRC5D for non-disease diagnosis purposes and / or treatment purposes, or in preparing products for preventing or treating tumors, or in preparing products for detecting GPRC5D; the tumor includes a GPRC5D-positive tumor.

21. The use according to claim 20, characterized in that The product includes at least one of immune cells, reagents, kits and drugs.

22. The use according to claim 20, characterized in that The products include pharmaceutical compositions.

23. The use according to claim 20, characterized in that The tumors include multiple myeloma.

24. A cell injection solution, characterized in that: It includes: The CAR-γδT cell of claim 19.